Final-Program-ATS-2023-AP.vp

WEDNESDAY • MAY 24

327

10:52 Role of Pro-Resolution Macrophages in Chronic Ozone Exposure Pulmonary Effectss D.L. Laskin, PhD, Piscataway, NJ 11:08 Arachidonic Acid Metabolic Pathways and Resolution Versus Progression of the Cardiometabolic Toxicity Induced by Particulate Matter. J.A. Araujo, MD, PhD, Los Angeles, CA 11:24 Discussion S.S. Nadadur, PhD, Research Triangle Park, NC

11:06 The Impact of Body Composition on Peri-Operative and Patient-Centered Outcomes in Lung Transplantation J.P. Singer, MD, MSci, san francisco, CA 11:18 The Clinical and Molecular Impacts of Lung Primary Graft Dysfunction J.F. Mcdyer, MD, Pittsburgh, PA

NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES, NIH OUTSIDE ORGANIZATION SESSION

AMERICAN LUNG ASSOCIATION AIRWAYS CLINICAL RESEARCH CENTERS OUTSIDE ORGANIZATION SESSION

L23 INFLAMMATION RESOLUTION PATHWAYS IN ENVIRONMENTAL PULMONARY HEALTH AND MORBIDITY 10:30 AM - 11:30 AM Walter E. Washington Convention Center Room 152 A-B (Street Level) Target Audience Clinicians, clinician scientists, basic research scientists, fellows and residents Objectives At the conclusion of this session, the participant will be able to: • gain knowledge on how exposure to environmental agents/chemicals may initiate and exacerbate preexisting inflammatory status • role of chronic exposure to environmental agents in chronic lung diseases • understanding of emerging and novel pathways involved in inflammation resolution The emerging interplay between unresolved inflammation and environmentally induced perturbations to inflammation resolution suggests exposure and inflammatory activation or exacerbation contributes to chronic lung disease progression. This session will provide an overview on the current state-of-science on inflammation resolution biology, and how chronic exposure to air pollutants, ozone, and fine particulate matter impact these processes. It will also provide an overview on how NIEHS and other NIH Institutes encourage research in this area to support potential therapeutic and interventional strategies aimed at promoting inflammation resolution to reduce environmental contributions to pulmonary morbidity and mortality. Chairing: S.S. Nadadur, PhD, Research Triangle Park, NC B.D. Levy, MD, ATSF, Boston, MA 10:30 Introduction S.S. Nadadur, PhD, Research Triangle Park, NC 10:36 SPM Pathway Responses to Lung Environmental Challenge B.D. Levy, MD, ATSF, Boston, MA

L24 STUDY UPDATES FROM THE AMERICAN LUNG ASSOCIATION’S AIRWAY CLINICAL RESEARCH CENTERS NETWORK 10:30 AM - 11:30 AM Walter E. Washington Convention Center Room 202 A (Level 2) Target Audience Physicians, clinical scientists, nurses, paraprofessionals, educators, health care providers Objectives At the conclusion of this session, the participant will be able to: • better counsel patients about the approach to management of asthma in obese patients. • describe the use of biomarkers for assessing the progression of emphysema. • incorporate home spirometry testing in management of patients with lung disease. The purpose of the session is to discuss ongoing research initiatives within the American Lung Association Airways Clinical Research Centers network. Chairing: L.J. Smith, MD, Chicago, IL R.A. Wise, MD, Baltimore, MD 10:30 Introduction L.J. Smith, MD, Chicago, IL 10:35 Relationship Between Cystic Fibrosis Transmembrane Conductance Regulator Function, Ventilation Heterogeneity, & Airway Obstruction in Young Adults S.S. Krishnan, MD, MPH, Valhalla, NY 10:45 TRIM Results Update C.R. Morris, PhD, Burlington, VT 10:55 Home Spirometry Validation Study E. Sugar, PhD, Baltimore, MD

ATS 2023 • Washington, DC